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Abstract 
Objectives To develop and validate a pragmatic risk score to predict mortality for patients admitted to 
hospital with covid-19.  
Design Prospective observational cohort study: ISARIC WHO CCP-UK study (ISARIC Coronavirus Clinical 
Characterisation Consortium [4C]). Model training was performed on a cohort of patients recruited 
between 6 February and 20 May 2020, with validation conducted on a second cohort of patients 
recruited between 21 May and 29 June 2020. 
Setting 260 hospitals across England, Scotland, and Wales. 
Participants Adult patients (≥18 years) admitted to hospital with covid-19 admitted at least four weeks 
before final data extraction. 
Main outcome measures In-hospital mortality. 
Results There were 34 692 patients included in the derivation dataset (mortality rate 31.7%) and 22 454 
in the validation dataset (mortality 31.5%). The final 4C Mortality Score included eight variables readily 
available at initial hospital assessment: age, sex, number of comorbidities, respiratory rate, peripheral 
oxygen saturation, level of consciousness, urea, and C-reactive protein (score range 0-21 points). The 4C 
risk stratification score demonstrated high discrimination for mortality (derivation cohort: AUROC 0.79; 
95% CI 0.78 - 0.79; validation cohort 0.78, 0.77-0.79) with excellent calibration (slope = 1.0). Patients 
with a score ≥15 (n = 2310, 17.4%) had a 67% mortality (i.e., positive predictive value 67%) compared 
with 1.0% mortality for those with a score ≤3 (n = 918, 7%; negative predictive value 99%). 
Discriminatory performance was higher than 15 pre-existing risk stratification scores (AUROC range 
0.60-0.76), with scores developed in other covid-19 cohorts often performing poorly (range 0.63-0.73). 
Conclusions We have developed and validated an easy-to-use risk stratification score based on 
commonly available parameters at hospital presentation. This outperformed existing scores, 
demonstrated utility to directly inform clinical decision making, and can be used to stratify inpatients 
with covid-19 into different management groups. The 4C Mortality Score may help clinicians identify 
patients with covid-19 at high risk of dying during current and subsequent waves of the pandemic.  
Study registration ISRCTN66726260 
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Introduction 
Disease resulting from infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
has a high mortality rate with deaths predominantly due to respiratory failure.
1
 As of 30
th
 July 2020, 
there are over 17 million confirmed cases worldwide and at least 660 000 deaths.
2,3
 As hospitals around 
the world are faced with an influx of patients with covid-19, there is an urgent need for a pragmatic risk 
stratification tool that will allow the early identification of patients infected with SARS-CoV-2 who are at 
the highest risk of death, to guide management and optimise resource allocation.  
Prognostic scores attempt to transform complex clinical pictures into tangible numerical values. 
Prognostication is more difficult when dealing with a severe pandemic illness such as covid-19, as strain 
on healthcare resources and rapidly evolving treatments alter the risk of death over time. Early 
information has suggested that the clinical course of a patient with covid-19 is different from that of 
pneumonia, seasonal influenza or sepsis.
4
 The majority of patients with severe covid-19 have developed 
a clinical picture characterised by pneumonitis, profound hypoxia, and systemic inflammation affecting 
multiple organs.
1
 
A recent review identified many prognostic scores used for covid-19,
5
 which varied in their setting, 
predicted outcome measure, and the clinical parameters included. The large number of risk 
stratification tools reflects difficulties in their application, with most scores demonstrating moderate 
performance at best and no benefit to clinical decision-making.
6,7
 It has been found that many novel 
covid-19 prognostic scores have a high risk of bias, which may reflect development in small cohorts, and 
many have been published without clear details of model derivation and testing.
5
 To our knowledge, a 
risk stratification tool is yet to be developed and validated within a large national cohort of hospitalised 
patients with covid-19. 
Our aim was to develop and validate a pragmatic, clinically relevant risk stratification score using 
routinely available clinical information at hospital presentation to predict in-hospital mortality in 
hospitalised covid-19 patients and then compare this with existing prognostic models. 
  
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted August 2, 2020. .https://doi.org/10.1101/2020.07.30.20165464doi: medRxiv preprint 
 5
Methods  
Study design and setting 
The International Severe Acute Respiratory and emerging Infections Consortium (ISARIC) WHO Clinical 
Characterisation Protocol UK (CCP-UK) study is an ongoing prospective cohort study in 260 acute care 
hospitals across England, Scotland, and Wales (National Institute for Health Research Clinical Research 
Network Central Portfolio Management System ID: 14152) performed by the ISARIC Covid-19 Clinical 
Characterisation Consortium (ISARIC-4C). The protocol and further study details are available online.
8
 
Model development and reporting followed the Transparent Reporting of a multivariate prediction 
mode for Individual Prediction or Diagnosis (TRIPOD) guidelines.
9
 The study was performed according to 
a pre-defined protocol (Appendix 1). 
 
Participants 
Patients aged ≥18 years old with a completed index admission to one of 260 hospitals in England, 
Scotland, or Wales were included.
8
 Reverse transcriptase-PCR was the only mode of testing available 
during the period of study. The decision to test was at the discretion of the clinician attending the 
patient, and not defined by protocol. The enrolment criterion “high likelihood of infection” reflected 
that a preparedness protocol cannot assume a diagnostic test will be available for an emergent 
pathogen. In this activation, site training emphasised importance of only recruiting proven cases. 
 
Data collection 
Demographic, clinical and outcomes data were collected using a pre-specified case report form. 
Comorbidities were defined according to a modified Charlson Comorbidity Index
10
; those collected were: 
chronic cardiac disease; chronic respiratory disease (excluding asthma); chronic renal disease (estimated 
glomerular filtration rate ≤30); mild-to-severe liver disease; dementia; chronic neurological conditions; 
connective tissue disease; diabetes mellitus (diet, tablet or insulin-controlled); HIV/AIDS, and 
malignancy. These were selected a priori by a global consortium to provide rapid, coordinated clinical 
investigation of patients presenting with any severe or potentially severe acute infection of public 
interest and enabled standardisation.  
Clinician-defined obesity was also included as a comorbidity due its likely association with adverse 
outcomes in patients with covid-19.
11,12
 Patients with missing data on all comorbidities were assumed to 
have no comorbidities. The clinical information used to calculate prognostic scores was taken from the 
day of admission to hospital.
13
 No generally accepted approaches exist to estimate sample size 
requirements for derivation and validation studies of risk prediction models. We used all available data 
to maximise the power and generalisability of our results. Model reliability was enhanced by our use of a 
validation cohort and sensitivity analyses 
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Outcomes 
The primary outcome was in-hospital mortality. This outcome was selected due to the importance of the 
early identification of patients likely to develop severe illness from SARS-CoV-2 infection (a ‘rule in’ test). 
We chose a priori to restrict analysis of outcomes to patients who were admitted more than four weeks 
before final data extraction (29
th
 June 2020) to enable most patients to complete their hospital 
admission. 
 
Independent predictor variables 
A reduced set of potential predictor variables was selected a priori including patient demographic 
information, common clinical investigations, and parameters consistently identified as clinically 
important in covid-19 cohorts following methodology described by Wynants et al.
5
 Candidate predictor 
variables were selected based on three common criteria:
14
 (1) patient and clinical variables known to 
influence outcome in pneumonia and flu-like illness; (2) clinical biomarkers previously identified within 
the literature as potential predictors in covid-19 patients; and (3) values were available for at least two-
thirds of patients within the derivation cohort. 
With the overall aim to develop an easy-to-use risk stratification score, an a priori decision was made to 
include an overall comorbidity count for each patient within model development giving each 
comorbidity equal weight, rather than individual comorbidities. Recent evidence suggests an additive 
effect of comorbidity in covid-19 patients, with increasing number of comorbidities associated with 
poorer outcomes.
15
 
 
Model development 
Models were trained using all available data up to 20
th
 May 2020. The primary intention was to create a 
pragmatic model for bedside use not requiring complex equations, online calculators, or mobile 
applications. An a priori decision was therefore made to categorise continuous variables in the final 
prognostic score.  
A three-stage model building process was used (Figure 1). Firstly, generalised additive models (GAMs) 
were built incorporating continuous smoothed predictors (thin-plate splines) in combination with 
categorical predictors as linear components. A criterion-based approach to variable selection was taken 
based on the deviance explained, the unbiased risk estimator, and the area under the receiver operating 
characteristic curve (AUROC) (see Appendix 2).  
Secondly, plots of component smoothed continuous predictors were visually inspected for linearity and 
optimal cut-points were selected using the methods of Barrio et al.
16
 
Lastly, final models using categorised variables were specified using least absolute shrinkage and 
selection operator (LASSO) logistic regression. L1-penalised coefficients were derived using 10-fold 
cross-validation to select the value of lambda (minimised cross-validated sum of squared residuals). 
Shrunk coefficients were converted to a prognostic index with appropriate scaling to create the 
pragmatic “4C” Mortality Score (where 4C stands for Coronavirus Clinical Characterisation Consortium). 
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Machine learning approaches were used in parallel for comparison of predictive performance. Given 
issues with interpretability, this was intended to provide a “best-in-class” comparison of predictive 
performance when accounting for any complex underlying interactions. Extreme gradient boosting trees 
were used (XGBoost). All candidate predictor variables identified were included within the model, with 
the exception of those with high missing values (>33%). Individual major comorbidity variables, defined 
as chronic cardiac disease; chronic respiratory disease (excluding asthma); chronic renal disease 
(estimated glomerular filtration rate ≤30 mL/min/1.73m
2
); moderate-to-severe liver failure (presence of 
portal hypertension); diabetes mellitus (diet, tablet or insulin-controlled) and solid malignancy, together 
with obesity, were retained within the model to determine whether their inclusion enhanced predictive 
performance. An 80%/20% random split of the derivation dataset was used to define train/test sets. The 
validation datasets were held back and not used in the training process. A mortality label and design 
matrix of centred/standardised continuous and categorical variables including all candidate variables 
was used to train gradient boosted trees minimising the binary classification error rate (defined as 
number wrong cases / number all cases). Hyperparameters were tuned including the learning rate and 
maximum tree depth to maximise the AUROC in the test set.  
Discrimination was assessed for all above models (4C and XGBoost model) using the AUROC in the 
derivation cohort, with 95% confidence intervals (CI) calculated using bootstrapping resampling (2000 
samples). An AUROC value of 0.5 indicates no predictive ability, 0.8 is considered good, and 1.0 is 
perfect.
17
 Overall goodness-of-fit was assessed with the Brier score,
18
 a measure to quantify how close 
predictions are to the truth ranging between 0 and 1, where smaller values indicate superior model 
performance. We plotted model calibration curves to examine agreement between predicted and 
observed risk across deciles of mortality risk to ascertain the presence of over- or under-prediction. Risk 
cut-off values were defined by the total point score for an individual which represented a low (<2% 
mortality rate), intermediate (2-14.9%) or high-risk (≥15%) groups, similar to commonly used pneumonia 
risk stratification scores.
19,20
  
Sensitivity analyses of missing values in potential candidate variables were performed using multiple 
imputation by chained equations, under the missing at random assumption. Ten sets, each with 10 
iterations, were imputed using available explanatory variables for both cohorts (derivation and 
validation). The outcome variable was included as a predictor in the derivation but not validation 
dataset. Model derivation was explored in imputed datasets. All models developed in the complete case 
derivation dataset were tested in the imputed validation dataset, with Rubin’s rules
21
 used to combine 
model parameter estimates.  
 
Model validation 
Patients entered subsequently into the ISARIC WHO CCP-UK study after 20
th
 May 2020 were included in 
a separate validation cohort (Figure 1). We determined discrimination, calibration, and performance 
across a range of clinically relevant metrics. To avoid bias in the assessment of outcomes, patients who 
admitted within four weeks prior to data extraction on 29
th
 June 2020 were excluded. 
A sensitivity analysis was also performed, with stratification of the validation cohort by geographical 
location. This geographical categorisation was selected based on well-described economic and health 
inequalities between the north and south of the UK.
22,23
 Recent analysis has demonstrated the impact of 
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deprivation on risk of dying with covid-19.
24
 As a result, population differences between regions may 
change the discriminatory performance of risk stratification scores. Two geographical cohorts were 
created, based on north-south geographical locations across the United Kingdom as defined by Hacking 
et al.
22
 A further sensitivity analysis was performed to determine model performance in ethnic minority 
groups, given reported differences in covid-19 outcomes.
25
 
All tests were two-tailed and p values <0.05 were considered statistically significant. We used R (version 
3.6.3) with the finalfit, glmnet, pROC, recipes, xgboost, rmda, and tidyverse packages for all statistical 
analysis. 
 
Comparison with existing risk stratification scores 
All derived models in the derivation dataset were compared within the validation cohort with existing 
scores. Model performance was assessed using the AUROC statistic, sensitivity, specificity, positive 
predictive value (PPV), and negative predictive value (NPV). Existing risk stratification scores were 
identified through a systematic literature search of EMBASE, WHO Medicus, and Google Scholar 
databases. We used the search terms “pneumonia”, “sepsis”, “influenza”, “COVID-19”, “SARS-CoV-2”, 
“coronavirus” combined with “score”’ and “prognosis”. We applied no language or date restrictions. The 
last search was performed on 1
st
 July 2020. Risk stratification tools were included whose variables were 
available within the database and had accessible methodology for calculation. 
Performance characteristics were calculated according to original publications, and score cut-offs for 
adverse outcomes were selected based on the most commonly used criteria identified during the 
literature search. Cut-offs were the score value for which the patient was considered at low- or high-risk 
of adverse outcome, as defined by study authors. Patients with one or more missing input variables 
were omitted for that particular score.  
A decision curve analysis (DCA) was also performed.
26
 Briefly, assessment of the adequacy clinical 
prediction models can be extended by determining clinical utility. Using DCA, a clinical judgment of the 
relative value of benefits (treating a true positive) and harms (treating a false positive) associated with a 
clinical prediction tool can be made. The standardised net benefit was plotted against the threshold 
probability for considering a patient “high risk” for age alone and the best discriminating models 
applicable to >50% of patients in the validation cohort.  
 
Patient and public involvement 
This was an urgent public health research study in response to a Public Health Emergency of 
International Concern. Patients or the public were not involved in the design, conduct, or reporting of 
this rapid response research. 
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Figure 1. Model derivation and validation workflow. 
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Results 
In the derivation cohort, we collected data from 34 692 patients between 6
th
 February 2020 and 20
th
 
May 2020. The overall mortality was 31.7% (10 998 patients). The median age of patients in the cohort 
was 74 (interquartile range (IQR) 59-83) years. 58.3% (20 184) were male and 75.3% (26 135) patients 
had at least one comorbidity. Demographic and clinical characteristics for the derivation and validation 
datasets are shown in Table 1.  
 
Model development 
In total, 41 candidate predictor variables measured at hospital admission were identified for model 
creation (Figure 1; Appendix 2). Following the creation of a composite variable containing all seven 
individual comorbidities and the exclusion of 13 variables due to high levels of missing values (Appendix 
3), 21 variables remained. 
Generalised additive modelling (GAM) identified eight important predictors of mortality; age, sex, 
number of comorbidities, respiratory rate, peripheral oxygen saturation, Glasgow Coma Scale (GCS), 
urea, and C-reactive protein (CRP) (for variable selection process, see Appendix 4). Given the a priori 
need for a pragmatic score for use at the bedside, continuous variables were converted to factors with 
cut-points chosen using component smoothed functions (on linear predictor scale) from GAM model 
(Appendix 5).  
On entering variables into a penalised logistic regression model (LASSO), all variables were retained 
within the final model (Appendix 6). Penalised regression coefficients were converted into a prognostic 
index using appropriate scaling (4C Mortality Score range 0-21 points; Table 2). 
The 4C Mortality Score demonstrated good discrimination for in-patient death within the derivation 
cohort (Table 3) with performance that approached that of the XGBoost model. The 4C Mortality Score 
showed good calibration (Calibration slope = 1; Figure 2) across the range of risk and no adjustment to 
the model was required.
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Table 1. Demographic and clinical characteristics for derivation and validation cohorts for patients 
hospitalized with covid-19. 
  Derivation cohort 
(n = 34 692) 
Validation cohort 
(n = 22 454) 
Mortality (%)  10 998 (31.7) 6428 (28.6) 
Age on admission (years) <50 4397 (12.7) 2825 (12.6) 
 50-59 4603 (13.3) 2630 (11.7) 
 60-69 5563 (16.0) 3155 (14.1) 
 70-79 7986 (23.0) 4971 (22.1) 
 ≥80 12 143 (35.0) 8873 (39.5) 
Sex at Birth Male 20 184 (58.3) 12 202 (54.4) 
 Female 14 411 (41.7) 10 211 (45.6) 
Ethnicity White 25 680 (83.2) 16 837 (85.0) 
 South Asian 1423 (4.6) 786 (4.0) 
 East Asian 269 (0.9) 138 (0.7) 
 Black 1108 (3.6) 765 (3.9) 
 
Other Ethnic 
Minority 
2387 (7.7) 1275 (6.4) 
Chronic cardiac disease  10 192 (32.0) 6853 (33.9) 
Chronic kidney disease  5451 (17.3) 3682 (18.4) 
Malignant neoplasm  3201 (10.2) 2144 (10.8) 
Moderate or severe liver disease  581 (1.9) 427 (2.2) 
Clinician-reported obesity  3250 (11.3) 2127 (11.9) 
Chronic pulmonary disease (not 
asthma) 
 5684 (17.9) 3671 (18.3) 
Diabetes  8245 (26.3) 4210 (22.0) 
Number of comorbidities 0 8557 (24.7) 5524 (24.6) 
 1 9633 (27.8) 6045 (26.9) 
 ≥2 16 502 (47.6) 10 885 (48.5) 
Respiratory Rate  22.0 (8.0) 20.0 (8.0) 
Peripheral oxygen saturation (%)  94.0 (6.0) 94.0 (5.0) 
Systolic blood pressure (mmHg)  125.0 (33.0) 129.0 (33.0) 
Diastolic blood pressure (mmHg)  70.0 (19.0) 73.0 (20.0) 
Temperature (°C)  37.3 (1.6) 37.1 (1.5) 
Heart Rate (bpm)  90.0 (27.0) 90.0 (28.0) 
Glasgow Coma Score  15.0 (0.0) 15.0 (0.0) 
pH  7.4 (0.1) 7.4 (0.1) 
Bicarbonate (mmol/L)  24.5 (4.5) 24.4 (5.0) 
Infiltrates on chest radiograph  13 984 (62.9) 8244 (61.1) 
Haemoglobin (g/L)  130.0 (29.0) 127.0 (31.0) 
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  Derivation cohort 
(n = 34 692) 
Validation cohort 
(n = 22 454) 
White cell count (10
9
/L)  7.4 (5.0) 7.6 (5.3) 
Neutrophil count (10
9
/L)  5.6 (4.6) 5.8 (4.9) 
Lymphocyte count (10
9
/L)  0.9 (0.6) 0.9 (0.7) 
Haematocrit (%)  35.0 (40.6) 25.2 (38.6) 
Platelet Count (10
9
/L)  215.0 (120.0) 223.0 (126.0) 
Prothrombin (seconds)  13.2 (3.0) 13.2 (3.2) 
Activated partial thromboplastin time 
(APTT) (seconds) 
 29.6 (8.6) 29.2 (8.8) 
Sodium (mmol/L)  137.0 (6.0) 137.0 (6.0) 
Potassium (mmol/L)  4.1 (0.8) 4.1 (0.7) 
Total bilirubin (mg/dL)  10.0 (7.0) 10.0 (7.0) 
Alanine aminotransferase (ALT) 
(units/L) 
 26.0 (27.0) 25.0 (26.0) 
Aspartate aminotransferase (AST) 
(units/L) 
 42.0 (41.0) 48.0 (53.0) 
Lactate dehydrogenase (Units/L)  432.0 (330.2) 416.5 (311.8) 
Glucose (mmol/L)  6.8 (3.1) 6.8 (3.2) 
Urea (mmol/L)  7.1 (6.4) 7.3 (6.8) 
Creatinine (µmol/L)  86.0 (53.0) 86.0 (56.0) 
Lactate (mmol/L)  1.5 (1.0) 1.5 (1.1) 
C-reactive protein (CRP) (mg/dL)  85.0 (121.0) 78.0 (120.0) 
Values stated as median with IQR in parentheses for continuous variables, patient number with percentage in 
parentheses for categorical variables. Comorbidities were defined using the Charlson Comorbidity Index, with the 
addition of clinician-defined obesity. Information on missing data contained within Appendix 3.
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Table 2. Final 4C Mortality Score for in-hospital mortality in patients with covid-19. Prognostic index 
derived from penalised logistic regression (LASSO) model.  
Variable 
 
4C Mortality 
Score 
Age (years) 
<50  
50-59 +2 
60-69 +4 
70-79 +6 
≥80 +7 
Sex at birth 
Female  
Male +1 
Number of comorbidities* 
0  
1 +1 
≥2 +2 
Respiratory rate (breaths/minute) 
<20  
20-29 +1 
≥30 +2 
Peripheral oxygen saturation on room air (%) 
≥92  
<92 +2 
Glasgow Coma Scale 
15  
<15 +2 
Urea (mmol/L) 
≤7  
7-14 +1 
>14 +3 
CRP (mg/dL) 
<50  
50-99 +1 
≥100 +2 
*Comorbidities were defined using the Charlson Comorbidity Index, with the addition of clinician-defined obesity 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted August 2, 2020. .https://doi.org/10.1101/2020.07.30.20165464doi: medRxiv preprint 
 14
Table 3. Model discrimination in derivation cohort. 
 
 
 
 
AUROC, area under receiver operator curve; CI, confidence interval.  
 
Model AUROC 95% CI Brier score 
4C Mortality Score 0.79 0.78 to 0.79 0.174 
Machine learning comparison  
(extreme gradient boosting [XGBoost]) 
0.81 0.79 to 0.82 0.179 
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Figure 2. A, distribution of patients across range of 4C Mortality Score in derivation cohort. B, observed inpatient mortality across range of 4C 
Mortality Score in derivation cohort. C, predicted versus observed probability of inpatient mortality (calibration; red line) with distribution of 
patients across predicted probability (vertical black lines) for 4C Mortality Score within derivation cohort. 
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Figure 3. Receiver operator curves (ROC) (A) and decision curve analysis (B) for most discriminating three models applicable to >50% of 
validation population, together with age alone (spline). B, Lines are shown for standardised net benefit at different risk thresholds of treating no 
patients (black) and treating all patients (grey).  
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Model validation 
The validation cohort included data from 22 454 patients collected between 21
st
 May 2020 and 29
th
 June 
2020 who had at least four weeks follow-up. The overall mortality was 28.6% (10 998 patients). The 
median age of patients in the cohort was 76 (interquartile range (IQR) 60-85) years. 12 202 (54.4%) were 
male and 16 930 patients (75.4%) had at least one comorbidity (Table 1). Missing data for predictor 
variables within the validation cohort are summarised in Appendix 7. 
Discrimination of the 4C Mortality Score in the validation cohort was similar to that of the XGBoost 
model. Calibration was also found to be excellent in the validation cohort (Calibration slope = 1; 
Appendix 8), with a similar Brier score to the derivation cohort (0.174). The 4C Mortality Score 
demonstrated good performance in clinically relevant metrics, across a range of cut-offs (Table 4). 
Four risk groups were defined with corresponding mortality rates determined (Table 5): low risk (0-3 
score; mortality rate 1.0%), intermediate risk (4-8 score; 9.8%), high risk (9-14 score; 35.2%), and very 
high risk (≥15 score; 66.8%). Performance metrics demonstrated a high sensitivity (99.8%) and negative 
predictive value (NPV; 99.0%) for the low-risk group, covering 6.9% of the cohort and a corresponding 
mortality rate of 1.0%. Patients in the intermediate risk group (score 4-8; n = 3007, 22.7%) had a 
mortality rate of 9.8% (NPV 90.2%). High-risk patients (score 9-14; n = 7009, 52.9%) had a 35.2% 
mortality (NPV 64.8), while patients scoring ≥15 (n = 2310, 17.4%) had a 66.8% mortality (positive 
predictive value 66.8%). 
 
Comparison with existing tools 
A total of 15 risk stratification scores were identified through a systematic literature search 
6,20,27–39 
The 
4C Mortality Score compared well against existing risk stratification scores in predicting inpatient 
mortality (Table 6). Risk stratification scores originally validated in patients with community-acquired 
pneumonia (n = 9) generally had higher discrimination for inpatient mortality in the validation cohort 
(e.g., A-DROP [AUROC 0.74; 95%CI 0.73-0.75], E-CURB65 [0.76; 0.74-0.79]) (Figure 3A) than those 
developed within covid-19 cohorts (n = 4: Surgisphere [0.63; 0.62-0.64], DL score [0.67; 0.66-0.68], 
COVID-GRAM [0.71; 0.68-0.74] and Xie score [0.73; 0.71-0.76]). Performance metrics for the 4C 
Mortality Score compared well against existing risk stratification scores at specified cut-offs (Appendix 
10). 
The number of patients in whom risk stratification scores could be applied differed due to certain 
variables not being available, either due to missingness or because they were not tested for/recorded in 
clinical practice. Seven scores could be applied to fewer than 2000 patients (<10%) in the validation 
cohort, due to the requirement for biomarkers or physiological parameters that were not routinely 
captured (e.g. lactate dehydrogenase [LDH]). 
Decision curve analysis demonstrated that the 4C Mortality Score had better clinical utility across the 
range of threshold risks compared with the best performing existing scores applicable to >50% of the 
validation cohort (A-DROP and CURB65).   
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Table 4. Performance metrics of 4C Mortality Score to rule-out mortality (A) and rule-in mortality (B) at 
different cut-offs in validation cohort. 
A 
 
B 
 
Number of patients 
at cut-off (%) 
TP TN FP FN Sensitivity Specificity PPV NPV 
Mortality 
(%) 
≥9 9319 (70.4) 4007 3620 5312 305 92.9 40.5 43.0 92.2 43.0 
≥11 7109 (53.7) 3489 5312 3620 823 80.9 59.5 49.1 86.6 49.1 
≥13 4495 (33.9) 2571 7008 1924 1741 59.6 78.5 57.2 80.1 57.2 
≥15 2310 (17.4) 1542 8164 768 2770 35.8 91.4 66.8 74.7 66.8 
TP, true positive; TN, true negative; FP, false positive; FP, false positive; PPV, positive predictive value; NPV, 
negative predictive value.  
 
 
Table 5. Comparison of mortality rates for 4C Mortality Score risk groups across derivation and 
validation cohorts 
 Derivation cohort    Validation cohort 
Risk group 
Number of 
patients (%) 
Mortality 
(%) 
Number of 
patients (%) 
Mortality 
(%) 
Low (0-3) 1275 (6.5) 1.5 918 (6.9) 1.0 
Intermediate (4-8) 4642 (23.8) 9.9 3007 (22.7) 9.8 
High (9-14) 10 430 (53.4) 38.1 7009 (52.9) 35.2 
Very high (≥15) 3175 (16.3) 69.8 2310 (17.4) 66.8 
Overall 19522 34.2 13244 32.6 
 
 
  
 
Number of patients 
at cut-off (%) 
TP TN FP FN Sensitivity Specificity PPV NPV 
Mortality 
(%) 
≤2 512 (3.9) 4310 510 8422 2 100.0 5.7 33.9 99.6 0.4 
≤3  918 (6.9) 4303 909 8023 9 99.8 10.2 34.9 99.0 1.0 
≤4  1353 (10.2) 4282 1323 7609 30 99.3 14.8 36.0 97.8 2.2 
≤6 2417 (18.2) 4196 2301 6631 116 97.3 25.8 38.8 95.2 4.8 
≤8  3925 (29.6) 4007 3620 5312 305 92.9 40.5 43.0 92.2 7.8 
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Table 6. Discriminatory performance of risk stratification scores within validation cohort to predict 
inpatient mortality in patients hospitalised with covid-19. See appendix 10 for other metrics.  
    Validation cohort (N = 22 454) 
 
Number of patients with 
required parameters 
AUROC (95% CI) 
SOFA 190 0.60 (0.50 - 0.69) 
qSOFA 17 716 0.62 (0.62 - 0.63) 
SMARTCOP 476 0.63 (0.58 - 0.68) 
Surgisphere* 17 359 0.63 (0.62 - 0.64) 
NEWS2 17 455 0.66 (0.65 - 0.67) 
SCAP 358 0.66 (0.60 - 0.71) 
DL score* 15 142 0.67 (0.66 - 0.68) 
CRB65 17 716 0.69 (0.68 - 0.69) 
COVID-GRAM* 1152 0.71 (0.68 - 0.74) 
DS-CRB65 17 127 0.72 (0.71 - 0.73) 
CURB65 14 318 0.72 (0.72 - 0.73) 
PSI 358 0.73 (0.67 - 0.78) 
Xie score* 1627 0.73 (0.71 - 0.76) 
A-DROP 14 338 0.74 (0.73 - 0.75) 
E-CURB65 1438 0.76 (0.74 - 0.79) 
4C Mortality Score* 13 244 0.78 (0.77 - 0.79) 
Machine learning 
comparison (XGBoost) 
- 0.79 (0.78 - 0.80) 
     *novel covid-19 risk stratification score 
 
Sensitivity analysis 
Multiple imputation was performed in both the derivation and validation cohorts (predictor variables n 
= 41). Prognostic models derived using from the multiply imputed derivation cohort had poorer 
performance than models derived using complete case data. This was true whether performance was 
assessed in the complete case or multiply imputed validation datasets. As a sensitivity analysis, the final 
model was assessed in the multiply imputed datasets. Discriminatory performance demonstrated a 
small reduction (≤0.02 change in AUROC) (Appendix 11) across both derivation and validation cohorts.  
After stratification of the validation cohort into two geographical cohorts (validation north and south; 
Appendix 12), discrimination remained similar for the 4C Mortality Score in both the North (AUROC 0.78, 
95%CI 0.77-0.79) and South (0.77, 0.76-0.79) subsets (Appendix 13).  
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Discussion 
Principal findings 
We have developed and validated the eight-variable 4C Mortality Score for in-patient death in a UK 
prospective cohort of 57 146 patients hospitalised with covid-19. The 4C Mortality Score uses patient 
demographics, clinical observations, and blood parameters that are commonly available at the time of 
hospital admission and can accurately predict patients at a high risk of in-hospital death. It compared 
favourably to other models, including ‘best-in-class’ machine learning techniques and demonstrated 
consistent performance across the validation cohorts including good clinical utility in a decision curve 
analysis. 
Model performance compared well against other generated models, with minimal loss in discrimination 
despite its pragmatic nature. A machine learning approach demonstrated a marginal improvement in 
discrimination, but at the cost of interpretability, the requirement for many more input variables, and 
the requirement for an app/website calculator limiting use at the bedside. The 4C Mortality Score 
demonstrated good applicability within the validation cohort (around 60% population) and consistency 
across all performance measures.  
 
Comparison with other studies 
The 4C Mortality Score contains parameters reflecting patient demographics, comorbidity, physiology, 
and inflammation on hospital admission. It shares characteristics with existing prognostic scores for 
sepsis and community-acquired pneumonia, as well as for scores developed in covid-19 patients. Altered 
consciousness and high respiratory rate are included in most risk stratification scores for sepsis and 
community-acquired pneumonia,
19,20,27,28,31,32,35
 while elevated urea is also a common component.
19,20,27
 
Increasing age is a strong predictor of inpatient mortality within our hospitalised covid-19 cohort and is 
commonly included in other existing covid-19 scores,
36,40,41 
together with comorbidity
36,40,41
 and elevated 
CRP.
39,42
 
Discriminatory performance of existing covid-19 scores applied to our cohort was lower than reported in 
derivation cohorts (DL score 0.74; COVID-GRAM 0.88; Xie score 0.98).
36,37,39
 The use of small inpatient 
cohorts from Wuhan, China for model development may have resulted in over-fitting,
 
limiting 
generalisability in other cohorts.
37,39
 The Xie score demonstrated the highest discriminatory power 
(0.73), including age, lymphocyte count, LDH and peripheral oxygen saturations. However, we were only 
able to calculate this score for <10% of the validation cohort, as LDH is not routinely captured on 
admission in the UK.  
Due to challenges of clinical data collection during an epidemic, missing data is common, with choice of 
predictors influenced by data availability.
39
 Complete case analysis often leads to exclusion of a 
substantial proportion of the original sample, subsequently leading to a loss of precision and power.
43
 
However, the assessment of missing data on model performance in novel covid-19 risk stratification 
scores has been limited
36
 or unexplored
37,39
, potentially introducing bias and further limiting 
generalisability to other cohorts. We found discriminatory performance in both derivation and 
validation cohorts remained similar after the imputation of a wide range of variables (41), further 
supporting the validity of our findings. 
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The presence of comorbidities is handled differently in covid-19 prognostic scores, either included 
individually,
39,41
 given equal weight,
36
 or found to have no predictive effect.
37
 Recent evidence suggests 
an additive effect of comorbidity in covid-19 patients, with increasing number of comorbidities 
associated with poorer outcomes.
15
 In our cohort, the inclusion of individual comorbidities within the 
machine learning model conferred minimal additional discriminatory performance, supporting the 
inclusion of an overall comorbidity count.
 
 
Strengths and limitations of this study 
The ISARIC WHO CCP-UK study represents the largest prospectively collected covid-19 hospitalised 
patient cohort in the world and reflects the clinical data available in most economically developed 
healthcare settings. We developed a clinically applicable score with clear methodology and tested it 
against existing risk stratification scores in a large hospitalised patient cohort. It compared favourably to 
other prognostic tools, with good to excellent discrimination, calibration and performance 
characteristics. 
The 4C Mortality Score has several methodological advantages over current covid-19 prognostic scores. 
The use of penalised regression methods, an event-to-variable ratio greater than 100 reducing the risk 
of model over-fitting,
44,45
 and the use of clinical parameters at first assessment increases the clinical 
applicability of the score and limits use of highly selective predictors prevalent in other risk stratification 
scores.
4,46
 In addition, the sensitivity analyses demonstrated that score performance was robust. 
Our study has limitations. First, we were unable to evaluate the predictive performance of a number of 
existing scores that comprise a large number of parameters (for example APACHE II
47
), as well as several 
other covid-19 prognostic scores that include computed tomography findings or uncommonly measured 
biomarkers.
5
 In addition, several potentially relevant comorbidities, such as hypertension, previous 
myocardial infarction and stroke
15
 were not included in data collection. Their inclusion might have 
impacted upon or improved 4C Mortality Score performance and generalisability.  
Second, a proportion of recruited patients had incomplete episodes and were thus excluded from the 
analysis. Selection bias is possible if patients with incomplete episodes, such as those with prolonged 
hospital admission, had a differential mortality risk to those with completed episodes. Nevertheless, the 
size of our patient cohort compares favourably to other datasets for model creation. Furthermore, the 
patient cohort on which the 4C Mortality Score was derived comprised hospitalised patients who were 
seriously ill (mortality rate of 30.5%) and were of advanced age (median age 74 years). Further external 
validation is required to determine whether the 4C Mortality Score is generalisable among younger 
patients and in settings outside the UK.  
 
Conclusions and policy implications 
We have derived and validated an easy-to-use eight-variable risk stratification score that enables 
accurate stratification of hospitalised covid-19 patients by mortality risk at hospital presentation. 
Application within the validation cohorts demonstrated this tool may guide clinician decisions, including 
treatment escalation.  
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The key aim of clinical risk stratification scores is to support clinical management decisions. Three risk 
classes were identified and demonstrated similar adverse outcome rates across the validation cohort. 
Patients with a 4C Mortality Score falling within the low-risk groups (mortality rate 1%) might be suitable 
for management in the community, while those within the intermediate-risk group were at lower risk of 
mortality (mortality rate 10%; 23% of the cohort) and may be suitable for ward-level monitoring. Similar 
mortality rates have been identified as an appropriate cut-off in pneumonia risk stratification scores 
(CURB-65 and PSI).
19,20
 Meanwhile patients with a score ≥9 were at high risk of death (43%), which may 
prompt aggressive treatment, including the commencement of steroids,
48
 and early escalation to critical 
care if appropriate.  
 
 
 
 
List of figures 
Figure 1. Model derivation and validation workflow. 
Figure 2. A, distribution of patients across range of 4C Mortality Score in derivation cohort. B, observed 
inpatient mortality across range of 4C Mortality Score in derivation cohort. C, predicted versus observed 
probability of inpatient mortality (calibration; red line) with distribution of patients across predicted 
probability (vertical black lines) for 4C Mortality Score within derivation cohort. 
Figure 3. Receiver operator curves (ROC) (A) and decision curve analysis (B) for most discriminating 
three models applicable to >50% of validation population, together with age alone (spline). B, Lines are 
shown for standardised net benefit at different risk thresholds of treating no patients (black) and 
treating all patients (grey).  
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End matter 
 
What is already known on this topic 
• There is a lack of robust, validated clinical prediction tools to identify patients with covid-19 who 
are at the highest risk of mortality 
• Given uncertainty about how to stratify covid-19 patients, there is considerable interest in risk 
stratification scores to support frontline clinical decision making 
• Available risk stratification tools however suffer from a high risk of bias, small sample size 
resulting in uncertainty, poor reporting and lack of formal validation 
 
What this study adds 
• The majority of existing covid-19 risk stratification tools performed poorly in our cohort – 
caution should be applied when using novel tools based on small patient populations to in-
hospital cohorts with covid-19 
• In contrast, our 4C (Coronavirus Clinical Characterisation Consortium) score is an easy-to-use 
and valid prediction tool for inpatient mortality, accurately categorising patients as being at low, 
intermediate, high, or very high-risk of death 
• This pragmatic and clinically applicable score outperformed other risk stratification tools and 
had similar performance to more complex models 
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Statements 
The study protocol is available at http://isaric4c.net/protocols; study registry 
https://www.isrctn.com/ISRCTN66726260. 
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